Legal & General Group
RNTX

Legal & General Group’s Rein Therapeutics RNTX Stock Holding History

Legal & General Group’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-44
Closed -$7K – 3390
2018
Q1 		$7K Hold
44
– – ﹤0.01% 3239
2017
Q4 		$9K Hold
44
– – ﹤0.01% 3240
2017
Q3 		$12K Buy
+44
New +$11K ﹤0.01% 3263

Other funds holding RNTX

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Legal & General Group's RNTX Position: Q2 2018 in Review

Legal & General Group sold out of Rein Therapeutics (RNTX) in Q2 2018, closing a stake of 44 shares — an estimated $7K sold.

Legal & General Group first reported a position in RNTX in Q3 2017 and held it in 3 quarters. The position peaked at $12K in Q3 2017. 20 funds tracked by Wall St. Rank hold RNTX as of Q2 2018.

  • Legal & General Group reported no remaining Rein Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Legal & General Group sold 44 Rein Therapeutics shares in Q2 2018, an estimated $7K.
  • Legal & General Group first reported a position in Rein Therapeutics in Q3 2017 and held it in 3 quarters.
  • Legal & General Group's Rein Therapeutics position peaked at $12K in Q3 2017.
  • 20 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2018.

Based on Legal & General Group's 13F filing for Q2 2018, filed 10 Aug 2018.